Omnicell (NASDAQ:OMCL) Price Target Cut to $36.00 by Analysts at JPMorgan Chase & Co.

Omnicell (NASDAQ:OMCL) had its target price cut by JPMorgan Chase & Co. from $44.00 to $36.00 in a research report report published on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock.

OMCL has been the topic of several other research reports. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th. Bank of America lowered their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Benchmark reaffirmed a “buy” rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Finally, Wells Fargo & Company lowered their price target on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $51.00.

Omnicell Trading Up 0.5 %

NASDAQ OMCL opened at $34.88 on Thursday. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of 129.19, a PEG ratio of 7.53 and a beta of 0.85. The stock’s 50 day moving average price is $39.94 and its two-hundred day moving average price is $42.98. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.75.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, analysts anticipate that Omnicell will post 1.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Omnicell by 22.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,181 shares of the company’s stock worth $5,306,000 after acquiring an additional 21,847 shares during the last quarter. Squarepoint Ops LLC increased its holdings in shares of Omnicell by 286.4% during the 4th quarter. Squarepoint Ops LLC now owns 149,717 shares of the company’s stock worth $6,665,000 after acquiring an additional 110,966 shares during the last quarter. Two Sigma Investments LP grew its holdings in Omnicell by 44.2% in the 4th quarter. Two Sigma Investments LP now owns 141,738 shares of the company’s stock valued at $6,310,000 after buying an additional 43,471 shares in the last quarter. Toronto Dominion Bank acquired a new position in Omnicell in the 4th quarter valued at $30,637,000. Finally, Point72 Hong Kong Ltd acquired a new position in Omnicell in the 4th quarter valued at $101,000. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.